NDA 017892 · Pfizer
Halcion
Triazolam · Oral · Benzodiazepine
NovelPriority reviewLast checked: Nov 20, 2026Latest source record: Jan 13, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1982
Nov 15, 1982
Approved uses
1
Original approval plus efficacy supplements
Registered trials
17
2 Phase 3, 1 recruiting
FAERS reports
4,040
3,259 serious, 662 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS; ABUSE, MISUSE, AND ADDICTION; and DEPENDENCE AND WITHDRAWAL REACTIONS • Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs in patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation [see Warnings and Precautions (5.1) , Drug Interactions (7.1) ] . • The use of benzodiazepines, including triazolam, exposes users to risks of abuse, misuse, and addiction, which can lead to overdose or death. Abuse and misuse of benzodiazepines commonly involve concomitant use of other medications, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse...
What it is approved for
From the label in effect Jul 10, 2026.
Triazolam is indicated for the short-term treatment of insomnia (generally 7 to 10 days) in adults. Triazolam is a benzodiazepine indicated for the short-term treatment of insomnia (generally 7 to 10 days) in adults.
Mechanism: Triazolam is a benzodiazepine. Triazolam exerts its effect for the short-term treatment of insomnia through binding to the benzodiazepine site of the gamma-aminobutyric acid-A (GABA A ) receptors in the brain and enhances GABA-mediated synaptic inhibition.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Nov 15, 1982 Original approval · Type 1 - New Molecular Entity · priority review Other Important Information from FDA
3 products under this application
- HALCION · TRIAZOLAM 0.125MG · TABLET, ORAL · Prescription · TE AB
- HALCION · TRIAZOLAM 0.25MG · TABLET, ORAL · Prescription · TE AB
- HALCION · TRIAZOLAM 0.5MG · TABLET, ORAL · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Triazolam" as an intervention, any sponsor and status, largest first.
- Pharmacovigilance in Gerontopsychiatric PatientsPivotal-lookingTerminated
Hannover Medical SchoolAcademic, hospital or other
NCT02374567 · 407 participants · Start Jan 2015 · Primary completion Jun 28, 2017
Drug: Phenobarbital; Phenytoin and 95 more · For: Dementia; Depression; Schizophrenia and 2 more
Sites: Augsburg, Germany; Berlin, Germany; Hanover, Germany · 5 sites in all
- Oral Versus Intravenous Sedation for Ocular ProceduresPivotal-lookingCompleted
Boston Medical CenterAcademic, hospital or other
NCT03246724 · 327 participants · Start Oct 16, 2017 · Primary completion Nov 30, 2019
Drug: Triazolam; Midazolam and 2 more · For: Surgery; Sedation
Sites: Boston, Massachusetts
- Oral Sedation in Vitreoretinal SurgeryStatus unknown
Rocky Vista University, LLCAcademic, hospital or other
NCT04346095 · 80 participants (planned) · Start Jun 2020 · Primary completion Oct 2020
Drug: Oral Sedatives with or Without Analgesia; Intravenous Sedatives with or Without Analgesia · For: Macular Holes; Intraocular Lens Opacification; Vitrectomy and 5 more
National Institute on Drug Abuse (NIDA)NIH
NCT00218166 · 78 participants · Start Aug 2001 · Primary completion May 2005
Drug: GABA Agonists · For: Cocaine-Related Disorders
Sites: Lexington, Kentucky
- Next-Day Residual Effects of Gabapentin, Diphenhydramine and Triazolam on Simulated Driving Performance in Normal VolunteersPivotal-lookingCompleted
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Pfizer (PFE)
NCT01888497 · 59 participants · Start Jul 29, 2013 · Primary completion Dec 14, 2013
Drug: Gabapentin; Diphenhydramine citrate and 2 more · For: Healthy
Sites: South Miami, Florida; Atlanta, Georgia · 4 sites in all
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT01780259 · 58 participants · Start Dec 2012 · Primary completion May 2013
Drug: Esketamine; Placebo and 1 more · For: Healthy
Sites: Merksem, Belgium
University of ManitobaAcademic, hospital or other
NCT03954483 · 42 participants (planned) · Start Oct 16, 2023 · Primary completion Oct 1, 2026
Drug: Buspirone 10 Mg Oral Tablet; Triazolam 0.25 MG Oral Tablet and 1 more · For: Anxiety
Sites: Winnipeg, Canada
Talphera, IncIndustry
NCT00894699 · 40 participants · Start Jun 2009 · Primary completion Sep 2009
Drug: Sublingual Sufentanil/Triazolam NanoTab™ (ARX-F03); Placebo NanoTab™ · For: Sedation; Anxiety; Pain
Sites: Pasadena, California
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug abuse336
- drug ineffective288
- toxicity to various agents220
- sopor208
- overdose182
- completed suicide172
- fatigue165
- nausea163
- malaise155
- drug interaction152
- fall144
- dizziness135
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 94 |
| 2005 | 76 |
| 2006 | 76 |
| 2007 | 59 |
| 2008 | 67 |
| 2009 | 76 |
| 2010 | 119 |
| 2011 | 129 |
| 2012 | 164 |
| 2013 | 185 |
| 2014 | 225 |
| 2015 | 250 |
| 2016 | 317 |
| 2017 | 288 |
| 2018 | 301 |
| 2019 | 276 |
| 2020 | 229 |
| 2021 | 221 |
| 2022 | 177 |
| 2023 | 262 |
| 2024 | 160 |
| 2025 | 143 |
| 2026 | 146 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Halcion (Triazolam)
2024 spending
$41K
Beneficiaries
83
202 claims
Per beneficiary
$493
$5.59 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $108,803 |
| 2021 | $96,192 |
| 2022 | $37,314 |
| 2023 | $41,808 |
| 2024 | $40,938 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Efficacy and safety of each class of sleep medication for major depressive disorder with insomnia symptoms: A systematic review and meta-analysis of double-blind randomized controlled trials.
Maruki T, Takeshima M, Yoshizawa K, et al. · Psychiatry Clin Neurosci 2025 · Systematic Review, Meta-Analysis
- Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine systematic review, meta-analysis, and GRADE assessment.
Maski K, Trotti LM, Kotagal S, et al. · J Clin Sleep Med 2021 · Meta-Analysis, Research Support, N.I.H., Extramural
- Insomnia in the elderly.
Montgomery P, Lilly J · BMJ Clin Evid 2007 · Systematic Review
- Adverse events of pharmacological interventions for insomnia disorder in adults: a systematic review and network meta-analysis.
Lu C, Geng Y, Guan X, et al. · Front Psychiatry 2025 · Systematic Review
- Dose determinants of rebound insomnia.
Roehrs TA, Zorick FJ, Wittig RM, et al. · Br J Clin Pharmacol 1986 · Clinical Trial, Controlled Clinical Trial
- Residual effects of medications for sleep disorders on driving performance: A systematic review and network meta-analysis of randomized controlled trials: NMA driving and hypnotics.
Fornaro M, Caiazza C, Rossano F, et al. · Eur Neuropsychopharmacol 2024 · Systematic Review, Network Meta-Analysis
Sponsor: Pfizer
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.